TARRYTOWN, N.Y. and
PARIS, March 28, 2017 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi will hold a
conference call for the financial community to discuss the U.S.
Food and Drug Administration approval of DUPIXENT® (dupilumab). The
conference call will take place today, March
28, 2017, at 4pm
ET/10pm CEST.
The conference call will include a presentation followed by a
Q&A session and will be accessible through an audio webcast at
www.regeneron.com and www.sanofi.com, and also via the following
telephone numbers:
U.S.: +1 (888) 660 6127
France: +33 (0) 8 00 90 93 22
UK: +44 (0) 800 028 8438
International: +1 (973) 890 8355
Access code: 92138426
A replay of the conference call and webcast will be archived on
the Companies' websites.
About Regeneron Pharmaceuticals, Inc.
Regeneron
(NASDAQ: REGN) is a leading science-based biopharmaceutical company
that discovers, invents, develops, manufactures and commercializes
medicines for the treatment of serious medical conditions.
Regeneron commercializes medicines for eye diseases, high
LDL-cholesterol, atopic dermatitis and a rare inflammatory
condition and has product candidates in development in other areas
of high unmet medical need, including rheumatoid arthritis, asthma,
pain, cancer and infectious diseases. For additional information
about the company, please visit www.regeneron.com or follow
@Regeneron on Twitter.
About Sanofi
Sanofi, a global healthcare leader,
discovers, develops and distributes therapeutic solutions focused
on patients' needs. Sanofi is organized into five global business
units: Diabetes and Cardiovascular, General Medicines and Emerging
Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare.
Sanofi is listed in Paris
(EURONEXT: SAN) and in New York
(NYSE: SNY).
Sanofi Genzyme focuses on developing specialty treatments for
debilitating diseases that are often difficult to diagnose and
treat, providing hope to patients and their families.
Contacts
Regeneron:
|
|
Media
Relations
|
Investor
Relations
|
Ilana
Tabak
|
Manisha
Narasimhan, Ph.D.
|
Tel: + 1 (914)
847-3836
|
Tel: +1 (914)
847-5126
|
Mobile: +1 (914)
450-6677
|
Manisha.narasimhan@regeneron.com
|
ilana.tabak@regeneron.com
|
|
|
|
Contacts
Sanofi:
|
|
Media
Relations
|
Investor
Relations
|
Ashleigh
Koss
|
George
Grofik
|
Tel:
908-981-8745
|
Tel: +33 (0) 1 53 77
94 69
|
ashleigh.koss@sanofi.com
|
ir@sanofi.com
|
|
|
U.S.
Communications
|
|
Carrie
Brown
|
|
Tel: +1 (908)
981-6486
|
|
Mobile: +1 (908)
247-6006
|
|
Carrie.Brown@sanofi.com
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/regeneron-and-sanofi-to-host-investor-conference-call-to-discuss-dupixent-dupilumab-approval-300430522.html
SOURCE Regeneron Pharmaceuticals, Inc.